Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Jan 2, 2014)
  • 8-K (Nov 12, 2013)
  • 8-K (Nov 7, 2013)
  • 8-K (Aug 6, 2013)
  • 8-K (Jul 9, 2013)
  • 8-K (Jun 24, 2013)

 
Other

Santarus 8-K 2005

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Ex-99.1
Santarus, Inc. (Form: 8-K)  

 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   March 17, 2005

Santarus, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 000-50651 33-0734433
_____________________
(State or other jurisdiction
_____________
(Commission
______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
10590 West Ocean Air Drive, Suite 200, San Diego, California   92130
_________________________________
(Address of principal executive offices)
  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   (858) 314-5700

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

(d) On March 17, 2005, Santarus' board of directors voted to increase the size of the board from seven to eight members. In addition, Ted W. Love, M.D. was appointed by Santarus’ board of directors to serve as a Class III director to fill the vacancy created by such increase. This appointment by the board of directors was based on the recommendation of its nominating/corporate governance committee. Dr. Love was recommended to the nominating/corporate governance committee by members of Santarus’ board of directors, and has been determined by Santarus’ board of directors to be independent, as independence is currently defined in Rule 4200(a)(15) of the Nasdaq listing standards. Dr. Love was also appointed to the nominating/corporate governance committee.

In connection with his appointment, Santarus granted to Dr. Love options to purchase 35,000 shares of common stock of Santarus at an exercise price of $5.24 per share under Santarus' Amended and Restated 2004 Equity Incentive Award Plan. One-third (1/3) of the total number of shares subject to the options will vest on the first, second and third anniversaries of Dr. Love's appointment as a director, subject to Dr. Love's continued service for Santarus.

Santarus issued a press release on March 18, 2005 announcing Dr. Love’s appointment to the board of directors, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.





Item 9.01. Financial Statements and Exhibits.

99.1 -- Press Release, dated March 18, 2005






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Santarus, Inc.
          
March 18, 2005   By:   Gerald T. Proehl
       
        Name: Gerald T. Proehl
        Title: President and Chief Executive Officer


Exhibit Index


     
Exhibit No.   Description

 
99.1
  Press Release, dated March 18, 2005
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki